Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

Abroad (travel likely)RecruitingPHASE2

Conditions

Recurrent Endometrial Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Miami, Miami, Florida, United States
Contact: Study coordinator (Navya Nair, MD, MPH) · navya.nair@miami.edu · 305-243-2233
Contact: Study coordinator (Abdulrahman Sinno, MD) · axs3193@miami.edu · 305-243-2233
Contact: Principal Investigator (Navya Nair, MD, MPH)

Study leads

Navya Nair, MD, MPH
Principal Investigator
University of Miami

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer

Cervical Cancer · Endometrial Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Head and Neck Squamous Cell Carcinoma HNSCC · Non-Small Cell Lung Cancer NSCLC · Esophageal Cancer

Abroad (travel likely)RecruitingPHASE1

Denver, United States · Sarasota, United States

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Endometrial Cancer

Abroad (travel likely)RecruitingPHASE2

Basking Ridge, United States · Middletown, United States

Study of EV for Recurrent Endometrial Carcinoma

Endometrial Cancer

Abroad (travel likely)RecruitingPHASE2

Milwaukee, United States